FUMAGALLI, ELENA

FUMAGALLI, ELENA  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 18 di 18 (tempo di esecuzione: 0.02 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study 2022 Fumagalli, ElenaCasali, Paolo G + Article (author) -
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors 2020 Sanfilippo, RobertaFabbroni, ChiaraFumagalli, ElenaCasali, Paolo G + Article (author) -
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers 2020 Fabbroni, ChiaraManglaviti, SaraFumagalli, ElenaCasali, Paolo GSanfilippo, Roberta + Article (author) -
Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas) 2019 Sanfilippo, RobertaProvenzano, SalvatoreFucà, GiovanniFumagalli, ElenaStacchiotti, SilviaCasali, Paolo G + Article (author) -
Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors 2019 Fumagalli, ElenaRadaelli, StefanoCasali, Paolo GFiore, Marco + Article (author) -
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 2019 Fumagalli, ElenaCasali, Paolo Giovanni + Article (author) -
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma : A Multicenter, International, Retrospective Study 2019 Fucà, GiovanniColia, VittoriaFumagalli, ElenaCasali, Paolo GiovanniSanfilippo, Roberta + Article (author) -
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 2018 Fumagalli, ElenaStellato, MarcoCasali, Paolo Giovanni + Article (author) -
Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors : long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels 2017 P. G. CasaliE. Fumagalli + Article (author) -
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 2017 E. FumagalliP. G. Casali + Article (author) -
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma 2017 Colia, VittoriaFiore, MarcoProvenzano, SalvatoreFumagalli, ElenaCasali, Paolo GSanfilippo, Roberta + Article (author) -
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 2017 E. FumagalliS. L. RenneS. StacchiottiP. G. Casali + Article (author) -
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma 2017 V. ColiaE. FumagalliS. ProvenzanoS. StacchiottiP. G. CasaliR. Sanfilippo + Article (author) -
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma 2014 Sanfilippo, RobertaMarrari, AndreaFumagalli, ElenaCasali, Paolo Giovanni + Article (author) -
Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib 2013 E. FumagalliG. PelosiA. Pierotti + Article (author) -
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? 2008 Negri, TizianaFumagalli, ElenaFiore, MarcoCasali, Paolo G + Article (author) -
Neuroprotective effects of the novel glutamate transporter inhibitor (-)-3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic acid, which preferentially inhibits reverse transport (glutamate release) compared with glutamate reuptake 2008 COLLEONI, SIMONAE. FumagalliP. ContiA. PintoM. De AmiciC. De Micheli + Article (author) -
Imatinib mesylate in chordoma 2004 Casali, Paolo G.Stacchiotti, SilviaFumagalli, Elena + Article (author) -